CSOP China Healthcare Disruption Index ETF (HKG:3174)
Hong Kong
· Delayed Price · Currency is HKD 2.864
+0.004 (0.14%)
At close: Jun 20, 2025, 4:00 PM HKT
70.48% (1Y)
| Assets | 388.60M |
| Expense Ratio | 1.50% |
| PE Ratio | 21.84 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +70.48% |
| Volume | 177,600 |
| Open | 2.882 |
| Previous Close | 2.860 |
| Day's Range | 2.844 - 2.892 |
| 52-Week Low | 1.586 |
| 52-Week High | 3.238 |
| Beta | 0.48 |
| Holdings | 23 |
| Inception Date | Jul 21, 2021 |
About 3174
CSOP China Healthcare Disruption Index ETF is an exchange-traded fund directly investing in companies. It prefers to invest in companies based out of Hong Kong. It primarily invests the healthcare- pharmaceutical and medical device companies.
Asset Class Equity
Category Total Market
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3174
Provider CSOP
Index Tracked WISE Samsung Group Value Index- KRW - Benchmark Price Return
Performance
3174 had a total return of 70.48% in the past year, including dividends. Since the fund's inception, the average annual return has been -21.83%.
Top 10 Holdings
74.85% of assets| Name | Symbol | Weight |
|---|---|---|
| Innovent Biologics, Inc. | 1801 | 10.45% |
| Sino Biopharmaceutical Limited | 1177 | 8.87% |
| Akeso, Inc. | 9926 | 8.45% |
| CSPC Pharmaceutical Group Limited | 1093 | 8.39% |
| WuXi AppTec Co., Ltd. | 2359 | 8.33% |
| Hansoh Pharmaceutical Group Company Limited | 3692 | 8.14% |
| WuXi Biologics (Cayman) Inc. | 2269 | 7.10% |
| Alibaba Health Information Technology Limited | 0241 | 5.77% |
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 2196 | 4.87% |
| Genscript Biotech Corporation | 1548 | 4.48% |